Five orally effective iron chelators of the 3-hydroxypyridin-4-one series have been administered intraperitoneally to ironoverloaded and nonoverloaded male mice at a dose of 200 mgl kgl24 h for a total of 60 days to investigate the effect on iron loading and toxicity. There was a significant reduction in hepatic iron at the end of the study in the iron-overloaded mice with all compounds studied using chemical iron quantitation (P < .001) and with Perls' stain (P < .01). Liver iron removal with the hydroxypyridinones ranged from 37% with CP20 to 63% with CP51, compared with 46% removal for desferrioxamine (DFO). There was no significant reduction in splenic or cardiac iron with any chelator. There were no EVE= hydroxypyridin-4-one iron chelators have s been shown to be effective at increasing the excretion of 59Fe with short-term studies in mice, rats, and rabbits by the oral route.' -' However the choice of which compound should be developed for use in humans is not ~lear.5.~ Kontoghiorghes et aI8 have chosen to develop 1,Zdimethyl-3-hydroxypyridin-4-one (CP2O)(L1) for initial studies in humans and increased urinary iron excretion has been shown in a number of iron-overloaded patients.8s9 However, there is evidence to suggest that this compound is both less active7 and produces a number of toxic effects not characteristic of the series of compounds as a w h~l e .~~~~'~ We have identified some compounds that appear to have a superior therapeutic safety margin than CP2O(L1) in short-term animal ~t u d i e s .~
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(Pheonix Pharmaceuticals, Gloucester, UK) by intramuscular injection and killed by exsanguination from the carotid artery. Macroscopic postmortem examination of the abdominal, thoracic, and intracranial tissues was recorded and weights of liver, spleen, kidneys, heart, and brain measured. Tissues were preserved in 10% buffered formalin. Tissue sections were cut at 5 pm and stained by hematoxylin and eosin (H&E). Coded samples were examined histologically so that their identities were unknown at the time of microscopy. Those with autolytic changes or poor fixation were excluded from analysis.
Tissues examined by light microscopy were bone marrow, eye, gall bladder, heart, kidney, liver, spleen, and stifle joint. Bone marrow was graded for the presence of hypoplasia and pigment deposits; the heart for pigment deposits; the spleen for pigment deposits, extramedullary hemopoiesis, and atrophy; and the liver for the presence of parenchymal pigment deposits, inflammatory cell infiltration, hepatocellular necrosis, and the presence of eosinophilic material in centrilobular hepatocytes.
Whole blood was taken under terminal anesthesia into labeled tubes and 130 KL aliquoted into polypropylene Eppendorf tubes containing 195 kg of dried dipotassium EDTA and mixed thoroughly. Samples were analyzed on a Coulter STK-R (Luton, UK) for hemoglobin (Hb), white blood cell count (WCC), platelet count (Plts), mean cell volume (MCV), and mean cell Hb (MCH). Samples with clots present were excluded from analysis. Blood films were also made on each sample and stained by Romanowsky staining. The remainder of the blood without anticoagulant was left for 30 minutes to allow clot retraction and then spun at 1,SOOg for 5 minutes to obtain serum for blood chemistry analysis.
Serum was frozen and stored at -20°C before analysis. Samples were analyzed on a multichannel analyzer for urea, creatinine, albumin, bilirubin, total protein, alanine transaminase (AST), and alkaline phosphatase (Alk Phos). Due to a small degree of hemolysis in the majority of the specimens, serum potassium and sodium were not measured. In
Hematologic investigations.
Blood chemistry investigations. some mice, insufficient blood was obtained for blood chemistry analysis.
After each organ had been weighed, two pieces of tissue were dissected from the main lobe of the liver and one from the apex of the heart and the spleen. These samples were lyophilized for 48 hours and the dry weight determined. After extraction of the non-heme iron with 3 mol/L hydrochloric acid (Aristar, BDH Chemicals, Poole, UK) and 10% trichloracetic acid (TCA; Aristar, BDH Chemicals)," the iron content of each sample was determined by atomic absorption spectroscopy at 248.3 nm using an air/acetylene flame for ironoverloaded tissue samples (Perkin Elmer 2280) and a graphite furnace (Perkin Elmer 1100 B) (atomization temperature 2,400"C) for samples with low iron content. Tissue iron was expressed as nanomoles per milligram of dry weight of tissue.
Perl's staining technique was performed on spleen, heart, and liver sections, analyzed 'blind,' and graded for intensity of Perl's staining. Liver sections were analyzed separately for granular and diffuse hemosiderin, representing reticuloendothelial and parenchymal deposits, respectively.
Continuous numerical data were examined for statistical significance by analysis of variance using Scheffe's test. This test allowed the contrasting of means and groups of means both between and within overloaded and nonoverloaded treatment groups of mice. Discontinuous histologic data were graded on a 1 through 5 increasing severity scale and the results were compared by x2 analysis for differences in the incidence of lesions and by Kruskal-Wallis one-way nonparametric analysis of variance for the comparison of severity grades.
Quantitation and distribution of tissue iron.

Statistical analysis.
RESULTS
Effects of chelators on weight gain and survival. Each animal was weighed weekly and the percent weight gain for each group after 60 days of treatment is tabulated in Table  1 , with a breakdown into overloaded and nonoverloaded animals. While all groups of mice gained weight, this was less so with all hydroxypyridinone compounds, both in iron-loaded and nonloaded animals. Weight gain was least with CP51, CP93, and CP21 and greatest with DFO. None of these differences in weight gain reached statistical significance and no consistent difference in weight gain between overloaded and nonoverloaded mice is seen.
The number of animals alive at the end of 60 days of treatment in each group is shown in Table 1 together with the days of dosing on which each mouse died. It can be seen that there were no deaths among the overloaded mice who received iron chelators, the only death being in one untreated control animal. By contrast, in the nonoverloaded group, seven animals died before the end of the study (P < .03, Fisher two-sided exact test).
Among the nonoverloaded mice, the proportion surviving to the end of the study period was less with some chelators than with others (Table 1) . Whereas there were no deaths with DFO, there were deaths with all the hydroxypyridin-4-ones studied except CP21. None of the deaths occurred immediately after administration of chelators but, generally, some hours later. In most, death was not preceded by modification of behavior. Animals observed to be clearly unwell were killed before the end of the study. In such cases, histologic examination was generally performed, but on occasions when the mice died before the The mean weight gain 2 SEM after 60 days of treatment of mice is shown, where n is the number of animals in each group. For animals dying before the end of the study, the number of doses after which this occurred is shown.
*There were significantly more deaths in the nonoverloaded mice than in the iron-nonoverloaded mice as a whole (P < .03).
end of the study, histologic examination was not always possible due to autolysis. Post mortem findings. Post mortem examination was performed macroscopically on each mouse at the end of the study and on selected organs microscopically. No consistent macroscopic abnormality was observed with any group at the time of post mortem. There was no significant change in organ weights of kidney or heart in any group. With the spleen, the mean weight in the CP51 nonoverloaded group (0.08 r 0.03 g) and the DFO nonoverloaded group was reduced from the control (0.12 ? 0.01 g), although this failed to reach significance. Liver weight was increased (1.59 ? 0.09 g) in CP21-treated overloaded mice, compared with the other iron-overloaded hydroxypyridinone-treated mice as a group (P = .04).
Liver, spleen, kidney, lung, bone marrow, heart, stifle joints, and eyes were examined microscopically on H&E-stained tissues in each animal. Microscopic examination of all these tissues except the liver showed no significant abnormality in any group. In the liver, however, treatment-related abnormalities were noted (Table 2). Hepatocytes immediately surrounding the central veins contained intracytoplasmic eosinophilic inclusion bodies in many of the animals treated with the hydroxypyridinones, but not with DFO. The presence of this material was not associated with evidence of necrosis or inflammatory cell infiltrate and no other abnormality was noted. The number of centrilobular hepatocytes affected and the quantity of intracytoplasmic eosinophilic material present varied between different groups of mice. In Table 2 it can be seen Histologic findings. For personal use only. on June 12, 2017. by guest www.bloodjournal.org From that the condition is most marked with CP51 and CP21 and least marked with CP20 and CP94.
Because adrenal enlargement had been noted in rats treated with some hydroxypyridinones" (authors' unpublished observations),z adrenal glands were examined in a supplementary study in groups of nonoverloaded mice (n = 3) after 60 doses of CP94, CP20, or DFO at 200 mg/kg. No enlargement or histologic differences were observed from control (PBS)-treated mice. Table 3 shows the serum values 2 the SEM for urea, creatinine, albumin, bilirubin (total), AST, Alk Phos, and total protein on overloaded and nonoverloaded mice, with the number of samples analyzed in parentheses. There is no statistically significant difference between control and chelator-treated mice for any values shown except for albumin, which is higher than control values with all hydroxypyridinones, reaching statistical significance where shown (Table 3 ). There is a wide variation for AST both in the control and treated groups. Of interest is the finding of a higher Alk Phos in the iron-overloaded than in the nonoverloaded animals as a group (P = .04). This difference is most marked in the control group and with CP20. Table 4 shows the values of Hb, MCV, MCH, red blood cell count (RCC), WCC, percentage neutrophils (% Neuts), percentage lymphocytes (% Lymphs), and Plts in overloaded and nonoverloaded mice. There is a statistically significant reduction in WCC with CP20-treated mice compared with control mice (P = .02) and compared with the other hydroxypyridinone-treated mice together (P = .0002). Although the WCC is less than Serum chemisby.
Hematologic findings.
in control animals with the other hydroxypyridinones and with DFO, this is not as marked and fails to reach statistical significance. Differential counting showed a leucopenia rather than a selective neutropenia in CP2O-treated mice. There is also a significant reduction in the Hb in CP20-treated mice compared with the other hydroxypyridinones as a group (P = .04) associated with a reduction in the RCC (P = .0002). The MCV is significantly increased in nonoverloaded mice administered CP20 compared with control (P = .001) but not in the corresponding overloaded group. Additionally there is a small decrease in the Plts in nonoverloaded mice treated with CP51, although this fails to reach significance from other groups of mice.
In the iron-overloaded mice, tissue iron distribution was examined by Perls' stain of liver, spleen, and heart and iron was also quantitated per milligram of dry weight of these tissues.
The degree of granular and diffuse Perl's positive material in the liver of the different groups of ironoverloaded mice, together with the statistical significance of the differences, is tabulated in Table 5 . All hydroxypyridin-4-ones and DFO produced a highly significant reduction in diffuse pigment deposits (P < .001), the most marked reduction being with CP51 and the least with CP20 and CP93. By contrast, the reduction in granular deposits is not significant for any compound.
Liver iron content per milligram of dry weight of tissue after 60 days of treatment with the chelators in ironoverloaded mice is shown in Fig 2A, all compounds producing a highly significant reduction in liver iron (P < .001). It can be seen that the changes in liver iron measured by Tissue iron content and distribution. Liver. atomic absorption parallel the reduction in diffuse pigment deposits shown with the Perl's stain (Table 5 ). CP51 is the most effective chelator by both techniques with 63% of liver iron removed. CP51 and CP21 were both significantly more effective than CP20 (P < .05) with 37% of liver iron removed (Fig 2A) . This result compares with iron removal of 44% for DFO and 50% for CP94. In contrast to the iron-overloaded mice, there was no significant reduction in liver iron in nonoverloaded mice treated with any compound (not shown). Figure 2B shows the effect of 60 days of treatment on splenic nonheme iron. It can be seen that no significant reduction in splenic iron was shown either by Perl's staining or iron quantitation. Figure 2C shows the quantity of nonheme iron per milligram of dry weight of heart tissue at the end of the study. Although there appear to be small reductions of iron content with CP21, CP51, CP93, and CP94, these were not statistically significant. Using the Perl's stain, the majority of stainable hemosiderin was not in the myocytes but in reticuloendothelial cells and significant differences in stainable iron could not be seen.
Spleen.
Heart.
DISCUSSION
A number of compounds have shown promise as effective oral iron chelators over the past two decades only to be rejected later because of unacceptable toxi~ity.~,'~~'' A thorough investigation of toxicity-efficacy relationships of putative oral iron chelators is therefore important before commencing formal toxicity testing and clinical trials. It is also clearly important to distinguish which toxic effects are protected against by iron loading and which are independent of it, so that chelators are not rejected as too toxic simply because they have chelated iron effectively, or because toxicity is found in nonoverloaded animals.
For these reasons we chose to study the relative efficacy and toxicity of several of our most promising bidentate hydroxypyridin-4-ones over 2 months in overloaded and represent effects caused directly by this group of cornnonoverloaded mice and to compare these with DFO, the pounds. The mechanism and nature of these liver changes only drug of proven clinical value. All compounds were are unclear, but the lack of a significant difference between administered IP, it having been shown previously that the overloaded and nonoverloaded mice suggests that the similar iron excretion was caused by the hydroxypyridin-4-changes are unlikely to be directly due to iron chelation. ones selected' whether administered orally or IP.
Similar cytoplasmic inclusions have been noted t o occur The finding that survival was significantly better in the spontaneously in the hepatocytes of otherwise normal mice iron-loaded hydroxypyridinone-treated mice than in the as well as in chemically treated mice and in benign nonloaded mice receiving the same dose suggests that iron hepatomas." The compounds associated with the most loading protects against the toxic effects of prolonged marked histologic changes in the liver, CP21 and CP51, are dosing with these compounds as well as against acute also those with the largest increase of liver weight in toxicity. This finding has important implications for the nonoverloaded mice. Enlargement of the adrenal glands design of more detailed toxicity testing in animals and for has been observed in rats administered CP20" and we have clinical studies in humans. There is a reduced weight gain in observed similar changes in male and female rats adminisboth iron-loaded and non-ironloaded mice with three of the tered CP94 for 28 days.*' However, the lack of adrenal hydroxypyridinone treatment groups (CP21, CP51, and changes in mice at similar doses in this study suggests that CP93) together with a smaller reduction in weight gain with there are interspecies differences in the metabolism or CP20 and CP94. While this fails to reach significance, the toxicity of these compounds. trend suggests that 200 mg/kg is not far below a dose
The range of serum chemistry analyses was limited by the causing more serious toxicity, and the deaths observed in volume of serum that was obtainable from the mice. The some groups of mice would support this.
absence of significant abnormalities of renal function sugDue to the number of compounds compared in this study, gest that the hydroxypyridin-4-ones are unlikely to have histology was limited to major organs and those at that time major toxic effects on this organ at this dose and this is considered to be potential targets for chelation toxicity.
confirmed by histology. The significance of the increase in Thus, the eyes were examined because DFO has been the serum albumin in hydroxypyridinone-treated mice is shown to be toxic in high doses clinically.'x The absence of unclear. There is no increase in AST despite the inclusions treatment-related abnormalities in the organs examined, in the liver. The higher Alk Phos in iron-overloaded with the exception of the liver, is encouraging. The inchcompared with nonoverloaded mice suggests that the oversions in the liver only occur with the hydroxypyridinones load is adversely affecting liver function. The finding that and are absent with DFO. They are therefore likely to this difference remains greatest with the compound that is It is unclear why the WCC should be depressed more with CP20 than with the other hydroxypyridinones studied. It is known that iron chelators may inhibit ribonucleotide reductase, arresting dividing cells in G1 or S phases of the cell cycle, and this has been shown for the hydroxypyridin-4-ones.'" However, it would be expected that CP20 would have had less of an effect than the other hydroxypyridinones studied because it removes less iron from cellsz' and from animals in short-term7 as well as in the present longer-term studies (Fig 2A) . One explanation for this difference may be that CP20 is metabolized differently from the hydroxypyridin-4-ones with larger substituents in either the 1 or 2 positions. Analysis of urine from rats treated with CP20 or CP94 shows significant differences in their metabolic degradation." The fact that the WCC was reduced in both the iron-overloaded and the nonoverloaded animals suggests that iron overload does not protect against this potentially toxic effect and that the mechanism may be independent of iron chelation. However, the raised MCV is only seen in the nonoverloaded mice (Table 4 ). Leucopenia has also been noted in rats administered CP20 at 200 mg/kg orally.23 How these changes relate to the occurrence of neutropenia and thrombocytopenia in two patientsz4 receiving CP20 is not clear as the reduction in mice is of both lymphocytes and neutrophils. Further studies on the mechanisms of these effects are therefore required.
One theoretical objection to the short-term animal models used for screening many chelators is that the radio-iron (usually "Fe) may overestimate the amount of iron mobilized. The demonstration that both DFO and the hydroxypyridin-4-ones can remove approximately half of the total liver iron in overloaded mice over a 2-month period suggests that 59Fe excretion using previous models'.' was representative of net iron excretion and not simply redistribution of 59Fe. In this context, it is interesting to note that the compound that showed the greatest efficacy in shortterm mouse studies using "Fe (eg, CP51)7 is the most effective in this subacute model. Conversely, the least active hydroxypyridinone in this study measuring liver iron removal, CP20, was also the least effective of these compounds in the short-term model measuring "Fe e~cretion.~ After 60 days of treatment at this dose, iron has not been removed significantly from the heart or the spleen (Fig 2B  and C) . Analysis of Perl's stain of the heart showed that the excess iron in the loaded mice was mainly epicardial and endocardial rather than myocardial in distribution (not shown). However, because most of the cardiac iron was not in the myocardium, this model may not reflect what happens in clinical iron overload. The results suggest that iron is chelated from hepatocytes before reticuloendothelial or cardiac iron is removed in significant quantities.
In conclusion, this study confirms findings in hepatocyte cultures" and in acute mouse models' that several of the hydroxypyridin-4-ones are at least as effective as DFO at mobilizing cellular iron, and that the liver is likely to be the major organ for iron chelation initially in vivo. Several of these or related hydroxypyridinones require further detailed toxicologic and metabolic studies to aid the selection of a compound for clinical use. On the basis of this and previous investigations, CP94 has the best balance between toxicity and efficacy of the hydroxypyridin-Cones studied by us to date. We have therefore chosen this compound for our initial evaluations of the efficacy, metabolism, and pharmacokinetics of the bidentate hydroxypyridin-4-ones in ironoverloaded human volunteers. Formal toxicity studies in two other animal species are in progress with this compound before clinical trials.
